HER2 DC1 vaccine

The HER2 DC1 vaccine is an investigational autologous dendritic cell-based immunotherapy developed by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of HER2-positive breast cancer. The vaccine is produced by collecting a patient's own monocytes via leukapheresis, which are then matured in vitro into type I polarized dendritic cells (DC1) and pulsed with MHC class II-restricted peptides derived from the HER2 (human epidermal growth factor receptor 2) protein. These DC1 cells are specifically designed to secrete high levels of interleukin-12 (IL-12), which promotes the restoration and expansion of anti-HER2 CD4+ Th1 immune responses. Administered via ultrasound-guided intranodal injection, the vaccine aims to stimulate a robust T-cell mediated attack against HER2-expressing tumor cells. It has been evaluated in clinical trials for various stages of the disease, including ductal carcinoma in situ (DCIS) and as a neoadjuvant or adjuvant treatment to prevent recurrence in patients with residual disease.

Other names

HER2-pulsed DC1 vaccineHER-2-pulsed DC1 vaccineHER 2-pulsed DC1 vaccineHER2-sensitized dendritic cell vaccineHER-2-sensitized dendritic cell vaccineHER 2-sensitized dendritic cell vaccineanti-HER2 DC1 vaccineanti-HER-2 DC1 vaccineanti-HER 2 DC1 vaccineHER2-pulsed DC1 booster vaccineHER-2-pulsed DC1 booster vaccineHER 2-pulsed DC1 booster vaccine